Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects With Severe Renal Impairment

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.00005-16
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

The Pharmacokinetics and Safety of Darapladib in Subjects With Severe Renal Impairment

British Journal of Clinical Pharmacology
Pharmacology
2015English

Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment

Antiviral Therapy
Infectious DiseasesPharmacology
2015English

Murepavadin, a Novel Antipseudomonal Antibiotic: Pharmacokinetics, Tolerability and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Safety and Efficacy of Ibrutinib in a Patient With Severe Renal Impairment

Hematology Reports
Hematology
2017English

Safety of High-Dose Daptomycin in Patients With Severe Renal Impairment

Therapeutics and Clinical Risk Management
2018English

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment

Journal of Clinical Pharmacology
Pharmacology
2015English

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib

Journal of Clinical Pharmacology
Pharmacology
2020English

Pharmacokinetics and Safety of a Single Dose of Stavudine (D4T) in Patients With Severe Hepatic Impairment.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care
DermatologyInfectious DiseasesImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy